AstraZeneca immunotherapy combo curbs liver cancer progression in Phase III win

AstraZeneca (NASDAQ:AZN) unveiled positive data from its late-stage EMERALD-3 clinical trial on Monday, demonstrating that adding its dual-immunotherapy regimen to standard localized therapy significantly slows disease progression in patients battling early-stage, unresectable liver cancer.

The findings, presented in an oral late-breaking abstract session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, mark a significant milestone in expanding systemic immunotherapy combinations into earlier intervention models for hepatocellular carcinoma (HCC).

The Phase III trial evaluated the company's approved checkpoint inhibitor Imfinzi (durvalumab) in combination with its CTLA-4 inhibitor Imjudo (tremelimumab-actl) alongside the targeted therapy lenvatinib and transarterial chemoembolization (TACE)—a common localized procedure that restricts blood flow to liver tumors.

Eligible participants consisted of patients with embolization-eligible, unresectable HCC whose disease had not yet spread beyond the liver itself.

In a pre-specified interim clinical analysis, the quadruplet combination utilizing AstraZeneca’s established STRIDE (Single Tremelimumab-actl Regular Interval Durvalumab) dosing architecture paired with lenvatinib and TACE achieved a 30% reduction in the risk of disease progression or death compared to utilizing TACE alone.

This key primary endpoint reduction was backed by a progression-free survival (PFS) hazard ratio of 0.70, with a 95% confidence interval of 0.57 to 0.86, demonstrating a high degree of statistical significance with a p-value of 0.0007.

Patients treated with the full multi-drug regimen achieved a median PFS of 13 months, compared to 9.8 months for those receiving standard TACE standalone treatment.

Clinical monitors noted that the observed survival and progression delays remained broadly consistent across all key pre-specified patient demographic and biological subgroups.

The trial also tracked overall survival (OS) as a major secondary benchmark.

While the survival data is still maturing, investigators recorded a positive early trend favoring the lenvatinib-containing STRIDE quadruplet regimen over standard care, producing an interim survival hazard ratio of 0.84 with a p-value of 0.1814.

AstraZeneca also evaluated an alternative triplet regimen that omitted lenvatinib, testing the STRIDE immunotherapy sequence combined solely with TACE.

Though this arm was not formally tested during this interim analysis window, it delivered highly clinically meaningful improvements across both primary and secondary indicators.

The STRIDE plus TACE arm achieved a median PFS of 12.9 months versus 8.1 months for its comparative TACE standalone cohort, logging an informal hazard ratio of 0.71 and a nominal p-value of 0.0062.

The overall survival trend for this triplet arm also separated cleanly from standard care, hitting an interim hazard ratio of 0.70 with a nominal p-value of 0.0233.

Furthermore, an exploratory comparative breakdown between the two active investigational cohorts showed that adding lenvatinib provided an additional progression-free advantage specifically within patients displaying non-viral tumor etiologies, posting a localized hazard ratio of 0.70.

The safety profiles recorded across both investigative treatment groups remained predictable and fully aligned with the established clinical profiles of each baseline drug asset.

Severe Grade 3 or higher adverse events resulting from all clinical causes occurred in 71.4% of patients inside the quadruplet lenvatinib arm and 64% of patients in the triplet STRIDE arm, compared to a baseline of 28.6% within the TACE standalone group.